Evaluation of Long-term Outcomes and its Related Factors in Patients with Immune-complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran
DOI:
https://doi.org/10.61186/Keywords:
Glomerulonephritis, Antigen-Antibody Complex, mmune Complex Crescentic Glomerulonephritis, Patient Outcome Assessment, PrognosisAbstract
Introduction. Immune-complex mediated glomerulonephritis (IC-GN) has a poor prognosis and commonly leads to kidney failure This study reports 20-year experience with the long-term outcomes of 222 Iranian IC-GN patients.
Methods. This single-center historical cohort study was conducted on patients who underwent kidney biopsies from 1998 to 2018 in Hasheminejad Kidney Center (HKC). Initial demographic, clinical, laboratory, and pathology data were extracted from the glomerulonephritis registry of HKC. Follow-up data was obtained by reviewing hospital and outpatient files, as well as phone calls. The primary outcomes were end-stage kidney disease (ESKD) and death, and the secondary outcomes were complete remission, partial remission, and stable chronic kidney disease.
Results. A total of 222 patients, (141 (63.5%) males, 81 (36.5%) females, mean age: 37.76 ± 15.71 years), were diagnosed with IC-GN. The most common causes were IgA nephropathy and lupus nephritis. Among all, 60.2% progressed to ESKD, 15.5% died, 13.1% achieved complete, and 18.5% achieved partial remission. The overall one-, three-, five-, and ten-years kidney survival rates were 52%, 42%, 38%, and 27%, respectively, with a significant difference between the IC-GN subtypes (P < .001). The highest kidney survival rate was found in lupus nephritis. Significant independent predictors of ESKD were the percentage of interstitial fibrosis and tubular atrophy (adjusted hazard ratio (aHR) = 1.022 [95% confidence interval (CI) = 1.012-1.033]), percentage of active crescents (aHR = 4.002 [95% CI = 2.066-7.752]), and initial serum creatinine level (aHR = 1.073 [95% CI = 1.035-1.112]) (P < .001 for all). Conclusion. There was a significant difference between the long-term survival of IC-GN types. Histopathologic features, and higher initial serum creatinine levels, were important predictors of poor outcome.
Downloads
References
1- Pendergraft WF, Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. Brenner & Rector's the kidney. 10th ed. Elsevier: Jeffrey Patterson; 2016. p.1072 & 1086.
2- Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis.1988;11:449-64.
3- Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987;31:790-4.
4- Chen S, Tang Z, Xiang H, et al. Etiology and Outcome of Crescentie Glomerulonephritis From a Single Center in China: A 10-Year Review. Am Kidney Dis. 2016;67: 376-83.
5- Nagaraju SP, Laxminarayana SLK, Kosuru S, et al. Clinicopathological Characteristics and Outcomes of Diffuse Crescentie Glomerulonephritis - A Single Center Experience from Southern India. J Clin Diagn Res. 2017;11:21-4.
6- Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant. 2000;15:1593-9.
7- Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14:890-5.
8- Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046-51.
9- Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563-9.
10- Choudhury TA, Singh RG, Usha, et al. Clinicopathologic spectrum of crescentic glomerulonephritis: A hospital-based study. Saudi J Kidney Dis Transpl. 2014;25:689-96.
11- Rampelli SK, Rajesh NG, Srinivas BH, Kumar KTH, Swaminathan RP, Priyamvada PS. Clinical spectrum and outcomes of crescentic glomerulonephritis: A single center experience. Indian J Nephrol. 2016;26:252-6.
12- Roy RR, Arju J, Sultana J, et al. Clinicopathological Spectrum and Treatment Outcome of Clinically Suspected Rapidly Progressive Glomerulonephritis: An Analysis of 35 Cases in a Tertiary Care Center, Bangladesh. J Ped Nephrol. 2019;7:1-8.
13- Lin W, Chen M, Cui Z, Zhao H. The Immunopathological Spectrum of Crescentic Glomerulonephritis: A Survey of 106 Patients in a Single Chinese Center. Nephron Clinical Practice. 2010:116:65-74.
14- Rianthavorn P. Chacranon M. Long-term renal outcome in pediatric glomerulonephritis associated with crescent formation. Clin Exp Nephrol. 2018;22:661-7.
15- Wu T, Peng J, Meng T, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18:3984-90.
16- Faye M, Lemrabott AT, Fall Kh, et al. Crescentic Glomerulonephritis in a Sub-Saharan Country: Clinical Presentation, Etiological and Evolutive Profile. Nephro-Urol Mon. 2017:9:60365.
17- Lim JH, Han MH, Kim YJ, et al. Novel histopathologic predictors for renal outcomes in crescentic glomerulonephritis. PLoS One. 2020;15:e0236051.
18- Kantauskaitė M, Laučytė-Cibulskienė A, Miglinas M. Histopathological Classification-A Prognostic Tool for Rapidly Progressive Glomerulonephritis. Medicina (Kaunas). 2018;54:17.
19- Piyaphanee N, Ananboontarick C, Supavekin S, Sumboonnanonda A. Renal outcomes and risk factors for ESKD in children with rapidly progressive glomerulonephritis. Pediatr Int. 2017;59:334-41.
20- Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7:e38904.
21- Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24:2118-25.
22- Mahmood SB, Aziz M, Malepati D, et al. Evaluating Sex Differences in the Characteristics and Outcomes of Lupus Nephritis: A Systematic Review and Meta-Analysis. Glomerular Dis. 2024;4:19-32.
23- Chen Z, Xu J, Wu J, et al. Prognostic analysis of crescentic glomerulonephritis with acute kidney injury: a single-center cohort with 5-year follow-up. Int Urol Nephrol. 2022;54:2375-83.
24- Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7:e000389.
25- Tian N, Zhou Q, Yin P, et al. Long-Term Kidney Prognosis and Pathological Characteristics of Late-Onset Lupus Nephritis. Front Med (Lausanne). 2022;9:882692.
26- Nasr SH, Radhakrishnan J, D'Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int. 2013;83:792-803.
27- Arivazhagan S, Rajasekar D, Gopalakrishnan N, et al. Clinicopathological profile and outcome of adult infection-related glomerulonephritis: A prospective follow-up study. Natl Med J India. 2020;33:260-4.
28- Sanathkumar HT, Fernando EM, Kurien AA, Srinivasaprasad ND, Suren S, Thirumalvalavan K. Clinical Profile, Histopathology, and Outcomes in Infection-Related Glomerulonephritis - Single-Center Experience. Indian J Nephrol. 2022;32:546-54.
29- Wu MJ, Shu KH, Chan LP, et al. Long-term clinical and morphological evaluation of primary membranoproliferative glomerulonephritis. Zhonghua Yi Xue Za Zhi (Taipei). 1996;57:34-41.
30- Agrebi I, Kammoun K, Dammak N, et al. Primary membranoproliferative glomerulonephritis in Sfax, Tunisia: epidemiologic profile and prognostic factors. Pan Afr Med J. 2021;38:218.
31- Syed R, Rehman A, Valecha G, et al. Pauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated Vasculitis. Biomed Res Int. 2015;2015:402826.
32- Sumida K, Ubara Y, Nomura K, et al. ANCA-associated crescentic glomerulonephritis with immune complex deposits. Clin Nephrol. 2012;77:454-60.
33- Haas M, Jafri J, Bartosh SM, et al. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis. 2000;36:709-18.
34- Haas M. Incidental healed postinfectious glomerulonephritis: a study of 1012 renal biopsy specimens examined by electron microscopy. Hum Pathol. 2003;34:3-10.
35- Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant. 1997;12:1017-27.
36- Neumann I, Regele H, Kain R, et al. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant. 2003;18:524-31.
37- Nasr SH, Said SM, Valeri AM, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299-308.
